BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boyle DL, Deprimo SE, Calderon C, Chen D, Dunford PJ, Barchuk W, Firestein GS, Thurmond RL. Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study. Inflamm Res 2019;68:261-74. [DOI: 10.1007/s00011-019-01218-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Rivellese F, Pitzalis C. Cellular and molecular diversity in Rheumatoid Arthritis. Semin Immunol 2022;:101519. [PMID: 35033462 DOI: 10.1016/j.smim.2021.101519] [Reference Citation Analysis]
2 Kim M, Choe Y, Lee H, Jeon MG, Park JH, Noh HS, Cheon YH, Park HJ, Park J, Shin SJ, Lee K, Lee SI. Blockade of translationally controlled tumor protein attenuated the aggressiveness of fibroblast-like synoviocytes and ameliorated collagen-induced arthritis. Exp Mol Med 2021;53:67-80. [PMID: 33408335 DOI: 10.1038/s12276-020-00546-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Nagarajan G, Thangam EB. Effect of H4R Antagonist N-(2-Aminoethyl)-5-Chloro-1H-Indole-2-Carboxamide (Compound A) in a Mouse Model of Allergic Asthma. Immunol Invest 2021;50:125-38. [PMID: 31985316 DOI: 10.1080/08820139.2020.1712415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]